and contradictory data have been also obtained on its cytogenetic action in cultured animal cells (Tsuda & Kato, 1977; . None the less, mutagenicity tests performed on microbial systems with several Cr(III) compounds were usually negative (Petrilli & De Flora, 1978b ; Kada et al., 1980; De Flora, 1981) .
Markedly different cytotoxic and cytogenetic activities of water-soluble Cr(VI), as potassium dichromate, and Cr(III), as chromium chloride, were shown in our laboratory, with mammalian cell cultures, on the basis of their effects on the physicochemical properties of nucleic acids (Tamino & Peretta, 1980; Tamino et al., 1981) , nucleoside uptake and nucleic acid synthesis (Levis et al., 1978a, b; Bianchi et al., 1979 Bianchi et al., , 1980 , the functions of plasmamembrane enzymes (Luciani et al., 1979) , the cell-division cycle (Majone & Rensi, 1979) , the induction of chromosome aberrations and sister-chromatid exchanges . A screening of the cytotoxic and clastogenic action of 11 water-soluble compounds of Cr(VI) and Cr(III) has been also carried out and is extended here by another 10 very soluble, barely soluble and highly insoluble compounds containing Cr(VI) and Cr(III), among which are several industrial pigments the carcinogenicity of which in the rat (Maltoni, 1976) and mutagenicity in bacteria (Petrilli & De Flora, 1978a, b; De Flora, 1981) have already been established (Table I) .
MATERIALS AND METHODS
Cells.-The heteroploid BHK 21 Syrian hamster fibroblast line adapted to growth in vitro in both monolayer and suspension, the heteroploid HEp-2 human epithelial-like line and the pseudodiploid CHO Chinese hamster fibroblast line, maintained in vitro as monolayers, were grown in Eagle's minimal essential medium (MEM) supplemented with 10% calf serum and routinely used as already described (Levis et al., 1978a,b;  Levis & 1Iajone, 1979) .
Cell growth and labelling.-The reduction in cell growth, based on the nucleic acid content (DNA + RNA) of treated cultures, and the inhibition of DNA, RNA and protein synthesis, based on the incorporation of labelled precursors, were determined, to evaluate the cytotoxic effects of Cr compounds in BHK cell cultures. Labelling with 2 ,uCi/ml thymidine-6-H3 (Radiochemical Centre, Amersham, gngland; 2 Ci/mM), uridine-5-H3 (2-5 Ci/mM) and L-leucine-4,5-H3 (0.5-1 Ci/mM), differential extraction and determination of soluble nucleotides and amino acids, nucleic acids and proteins, and evaluation of the actual rates ofmacromolecular syntheses and changed uptake of soluble precursor due to Cr action, were performed by the procedures already described (Levis et al., 1978a,b ; . Mitotic studies.-HEp cell cultures were grown on coverslips, fixed in Carnoy's fluid and stained with Mayer's haemalum, as already described (Majone & Rensi, 1979) .
Three to four thousand cells were then examined for each dose level and each time interval, and the mitotic index (the ratio of all mitoses to the total number of cells) and the frequencies of each mitotic phase (the ratios of cells in each phase to total mitoses) were determined.
Chromosome preparations.-3 x 10-5M bromodeoxyuridine (Sigma, St Louis, Mo., U.S.A.) was incorporated for 2 cell cycles (32 h) in CHO cell cultures, and then metaphase cells were prepared as detailed elsewhere , so that chromosome aberrations and sister-chromatid exchanges (SCE) were scored on the same cell preparations.
Chromium determinations.-Cr(VI) was determined spectrophotometrically by the direct coloured reaction with 1,5-diphenylcarbazide (DPCA) (Riedel De Haen, Hannover, West Germany), and Cr(III) by the same reaction after oxidation to Cr(VI) with potassium permanganate, as already described (Levis et al., 1978a, b; . The colorimetric method was sensitive to 0-01 ,ug Cr(VI) per ml final solution with 5cm spectrophotometric cells, and followed Beer's law up to a concentration of 1 jug Cr(VI) per ml final solution (or 1 pt/106). Standard calibration curves, made with potassium dichromate and chromium chloride as highly soluble Cr(VI) and Cr(III) salts, gave reliable results for the direct Cr(VI) determination by DPCA in Hanks' balanced salt solution (HBSS) and MEM, provided that phenol red was not added to the solutions as an indicator of pH, as well as for total Cr determination (Cr(VI) + Cr(IJJ)) in HBSS, MEM and treated cells, after wet decomposition of the samples by mineralization at 180NC for 2-3 h with nitric acid: sulphuric acid: perchloric acid (3:1:1) and oxidation with potassium permanganate. The last procedure has been used also for Cr(VI) and Cr(III) determination in biological samples both by atomic absorption spectrophotometry (Feldman et al., 1967) and gas chromatography (Savory et al., 1970) Tables I, IV, V) , Cr compounds were directly suspended in the growth medium used for treatments. In the experiments on the induction of chromosome aberrations and SCE in CHO cells, almost complete solubilization was obtained in N HCI for Cr(III) compounds and 0-5N NaOH for Cr(VI) compounds, after which they were diluted with MEM to the final concentrations specified in Table IX (Maltoni, 1976) and mutagenicity in bacteria (Petrilli & de Flora, 1978a,b; de Flora, 1981 Tables IV, V , VII and Fig. 3 ). The cytotoxic and clastogenic effects were usually determined just at the end of Cr treatments, but sometimes the treated cells were washed with HBSS and incubated with normal growth medium, so that the effects of Cr were determined at different times after the end of treatment (see Fig. 3 . Exposure to all the concentrations of potassium dichromate and zinc yellow, as well as to 0 5 mg/ml of Cr orange, produces the maximum cytotoxicity of Cr(VI) treatments, all the cells being killed, whereas the same effect is produced only by exposure to 0 5 mg/ml of chromite, of the Cr(III) compounds (Table III) .
Treatments with 0*15 mglml of Cr yellow and molybdenum orange significantly inhibit cell growth and macromolecular syntheses, whereas neochromium, Cr alum and Cr sulphate produce comparable inhibition at a higher concentration (0.5 mg/ml). On the other hand Cr chloride, though the only completely soluble Cr(III) compound, has no cytotoxicity. DNA synthesis is the most sensitive to all Cr compounds, RNA and protein syntheses being always less inhibited.
As most of the compounds were scarcely soluble or even highly insoluble in water, preincubation for 48 h in MEM with BHK cell suspensions or in MEM without cells was carried out, to facilitate solubilization of Cr(VI) and complex formation between Cr(III) and medium components or cell metabolites. At the end of preincubation, the cells were discarded and the solubilized Cr(VI) and Cr(III) contents were determined in the filtered MEM, which was then used to treat fresh BHK monolayers for 2 h. nificantly inhibits DNA and RNA, but not protein synthesis. The other Cr(VI) and Cr(III) compounds, however, are scarcely active even at 0.5 mg/ml, as they partially inhibit nucleic acid synthesis only when preincubated in cell-free MEM, with the exception of CrCl3 which is completely inactive throughout.
Concerning the amounts of Cr solubilized during preincubation, it can be observed ( Table IV) that potassium dichromate and CrCl3 are completely soluble in MEM; 0-5 mg/ml of these compounds correspond to 176.9 p,g/ml of Cr(VI) and 97-7 ,g/ml of Cr(I11) respectively, which are very close to the observed values. Partial solubilization of Cr(III) is obtained with neochromium and Cr alum, whereas preincubation of the other compounds gives very low levels of soluble Cr. Among 5   100   59  72  100 100  93  100  100 100  81  100  100 100  17  24  26  47  94 100  39  52  42  68  90  100  93  100  100 100  84  100  87  100  100 100   100 100  100  100  100 100  100  100  100  100  100 100   4  25  4  42  52 100  7  49  16  64  35  100  100 100  100  100  68  96  100 100  100 100   100  100  100  100  100  100  40  62  100  69  100  100  100  100  100  100 Table III . (Table V) . Zinc yellow strongly inhibits nucleic acid synthesis even after 2h preincubation, and its cytotoxicity increases with longer preincubations. Cr orange is much less active, giving considerable inhibition of nucleic acid synthesis only after 6 days of preincubation. Again the cytotoxicity is greater after preincubation in cell-free MEM than in MEM with cells. An increasing amount of Cr(VI) is solubilized with increasing preincubation time in MEM, and is reduced to Cr(III) in the presence of cells. It appears also in Table V that preincubation in MEM with cells gives more solubilized total Cr than preincubation in MEM alone, which is an almost general rule for all Cr compounds used (see Table  IV ).
Chromium accumulation and stability in BHK cells
The accumulation of Cr in BiHK cell suspensions was determined after exposure for up to 6 h to the very soluble Cr(VI) and Cr(II) compounds potassium dichromate and CrCl3 (Fig. 2) . Treatment with 150 pg/ml Cr(V7I) pigments did not permit the analysis of chromosome aberrations, because of the marked inhibition of cell growth and the severe delay of the mitotic cycle. The frequency of chromosome aberrations is also increased after treatment with Cr(III) compounds, being about doubled after exposure to 25-150 ,tg/ml.
On the other hand, the frequencies of SCE are significantly increased by all Cr(VI) compounds and by chromite, but not by the other Cr(III) compounds. The increase is of the same order as that already obtained with other Cr(VI) salts, and it is much lower than that induced by mitomycin C, which was the positive control for the response of our cell system to the induction of chromosome damage .
In a parallel experiment, CHO cells have been exposed to Cr(VI) and Cr(III) compounds previously solubilized with HCI and NaOH and then diluted in the medium used for treatments. It can be seen (Table IX) (Sirover & Loeb, 1976; Tkeshelashvili et al., 1980) , point mutations in bacteria (Venitt & Levy, 1974; Nishioka, 1975; Green et al., 1976; Petrilli & De Flora, 1978b; Lofroth, 1978; Nakamuro et al., 1978; Nestmann et al., 1979; Kada et al., 1980; Kanematsu et al., 1980; De Flora, 1981) , yeast (Bonatti et al., 1976 ) and mammalian cells (Newbold et al., 1-979); and gene conversion (Bonatti et al., 1976) and mitotic reconmbination (Nestmann et al., 1979) in yeasts; chromosomal aberrations (Tsuda & Kato, 1977; Nakamuro et al., 1978; Newbold et al., 1979; Umeda & Nishimura, 1979; Douglas et al., 1980) ; SCE Majone & Rensi, 1979; MacRae et al., 1979; Douglas et al., 1980) ; DNA damage Tamino & Peretta, 1980; Douglas et al., 1980; Tamino et al., 1981) ; DNA repair synthesis ; morphological transformation (Fradkin et al., 1975; Tsuda & Kato, 1977; and enhancement of viral transformation in cultured mammalian cells; increased frequency of micronuclei and chromosomal aberrations in cells of rodents treated in vivo (Wild, 1978) as well as in lymphocytes of professionally exposed workers (Bigaliev et al., 1977) . Cr(VI) compounds gave positive results in the mouse "spot" test (Knudsen, 1980) and transformed Syrian hamster cells when injected into pregnant hamsters , thus indicating that they are also transplacental mutagens. When tested for their ability to induce cytotoxic (White et al., 1979) and mutagenic effects (Petrilli & De Flora, 1978a; Koshi, 1979; Knudsen, 1980; Stern, 1980; De Flora, 1981) , industrial pigments and welding fumes from Cr-using processes have been shown to be uniquely active, owing to the presence of Cr(VI).
On the contrary, Cr(III) salts are usually inactive in mutagenicity tests (Venitt & Levy, 1974; Nishioka, 1975; Petrilli & De Flora, 1978b; Kada et al., 1980; Kanematsu et al., 1980; De Flora, 1981) except in systems involving a direct interaction with DNA purified in vitro, such as damage shown by the alteration of its physico-chemical properties (Tamino & Peretta, 1980; Tamino et al., 1981) and increased error frequency during replication (Sirover & Loeb, 1976; Tkeshelashvili 1980) . The only frequent cytogenetic effect in mammalian cells treated in vitro with Cr(III) compounds is the increase of chromosome aberrations (Nakamuro et al., 1978; Levis & Mlajone, 1979 ; see also the present data), but it is obtained with doses much higher than the active Cr(VI) concentrations, and could be related to an indirect effect produced by such extreme conditions, e.g. by the release of lysosomal nucleases. Moreover, it is found in cell lines permanently adapted to growth in vitro, which are characterized by chromosomal instability. Toxicity data in animals (IARC, 1980) and cytotoxicity studies in cultured mammalian cells White et al., 1979 ; see also the present results) accordingly show that Cr(VI) is 100 or even 1000 times more active than Cr(III).
On this basis, the cytotoxic, mutagenic and carcinogenic effects of Cr have been attributed to its oxidized state (Levis et al., 1978a, b; Norseth, 1979; Bianchi et al., 1979; Langard, 1980; Petrilli & De Flora, 1 980; Leonard & Lauwerys, 1980) . The positive mutagenicity occasionally obtained with Cr(III) compounds (Nakamuro et al., 1978) cannot be related to conversion of Cr(III) to the active Cr(VI) form, which was described in plant cells (Skeffington et al., 1976 ), but which is generally deemed not to take place in animal systems (Mertz, 1969; Norseth, 1979; Langard, 1980; Leonard & Lauwerys, 1980) . The shift of Cr(III) to Cr(VI) was shown not to occur in vitro with different metabolic systems, and was obtained only by treating with a strong oxidizing agent such as potassium permanganate (Petrilli & De Flora, 1978b) (Petrilli & De Flora, 1978b;  see also the present data on chromite contamination) and even for reagentgrade laboratory products (Levis & Maj one, 1979) , which accounts for the genetic activity observed with those agents; the actual oxidation state of Cr in the compounds used in the carcinogenicity and mutagenicity tests is rarely checked. The conversion of Cr(III) to Cr(VI) in the organism has been postulated by Grogan (1957) but it should be a slow process, occurring only under particular conditions of retention and accumulation of the metal, and only in tissues with a very low reducing potential (Petrilli & De Flora, 1978b) . This could account for the carcinogenic action exerted at the implant site by Cr(III) compounds administered i.m. or s.c. (Maltoni, 1976; IARC, 1980) .
The results of the present investigation confirm the marked differences in cytotoxic and cytogenetic activity of Cr(VI) and Cr(III) which we had already noticed on treating mammalian cell cultures with water-soluble Cr compounds (Levis et al., 1978b; Majone & Rensi, 1979; Luciani et al., 1979; Bianchi et al., 1980) and can contribute to a better understanding of the mechanisms of Cr carcinogenic action.
The mutagenic action of the compounds used in the present investigation has been determined in the Salmonella/ microsome test by De Flora (1978a,b) and De Flora (1981) Maltoni (1976) , who injected them s.c. into rats. Insoluble Cr(VI) pigments, namely Cr yellow, Cr orange and molybdenum orange, raised the frequency of sarcomas at the site of injection from 0% in the controls to 65-90%, whereas Cr(IIJ) pigments neochromium and Cr alum produced lower but significant increases (20-25%). The same chromite that was cytotoxic and clastogenic in the present study and mutagenic in the study of Petrilli & De Flora (1978b) owing to traces of Cr(VI), failed to induce tumours in any of the 40 animals tested by Maltoni (1976) but, as in the case of zinc yellow, necrosis was produced at the site of injection (Maltoni, personal communication) , most probably due to the oxidizing action of soluble Cr(VI) in the administered compounds.
In contrast to the low cytotoxicity of Cr(III), much higher Cr levels are detected in the cells incubated with Cr(III) than with the same Cr(VI) concentrations (Fig.  2) . As for treatments with Cr(VI), the amounts of cell-linked Cr are higher when the incubation is made in MEM than in HBSS, because greater amounts of Cr(III) are produced in MEM by the reduction of Cr(VI) by components of the growth medium (Levis et al., 1978b) . The opposite is found for incubations with Cr(III) (Fig.  2) , probably because ligand formation with cell constituents is more limited for Cr(III) complexes involving MEM components than for Cr(III) chelates and olates present in the simplified HBSS solution (Mertz, 1969) .
The different biological activities of Cr(VI) and Cr(III) are certainly related to a marked difference in Cr uptake through the cell membrane, very active mechanisms for Cr(VI) transport having been demonstrated, which are accomplished by specific chromate-ion permeases (Vallee, 1969) , whereas the transport of Cr(III) complexes and chelates is extremely limited (Mertz, 1969; Norseth, 1979; Langard, 1980) . A very rapid accumulation of Cr(III), even much faster than that of Cr(VI), was described in plant root cells (Skeffington et al., 1976) , where it was shown that most of the absorbed Cr(VI) was in the soluble fraction, while most of the Cr(III) was in the insoluble membrane fraction, as in the present experiments (see Fig. 2 and Table VI) . A multiplicity of cation-binding sites in the cell walls and cell membrane could adsorb Cr(III), which may explain why it is less toxic and transported less than Cr(VI) inside the cell, though more readily accumulated on the cell surface. The present experiments (Table VI) Whereas the cytotoxic action of Cr (VI) has been attributed to the oxidation of biological targets placed mainly on the cell membrane (Levis et al., 1978a,b; Bianchi et al., 1980; Luciani et al., 1979) , its genetic activity could depend on the interaction of intracellularly reduced Cr(III) with specific targets on the DNA molecule (Levis et al., 1978a,b; Norseth, 1979; Langard, 1980; Petrilli & De Flora, 1-980; Bianchi et al., 1980; Leonard & Lauwerys, 1980) . Interactions with nucleic acids, giving changes of their physicochemical and biochemical properties which could be relevant to the production of genetic changes, have been shown to occur both when purified nucleic acids are treated in vitro with Cr(III) compounds (Sirover & Loeb, 1976; Tamino & Peretta, 1980; Tkeshelashvili et al., 1980 : Tamino et al., 1981 and when cells are treated with Cr(VI) compounds Douglas et al., 1980; Tamino et al., 1981) . Owing to the stability of Cr(III) chelates and coordination complexes and to their very low exchange rate with biological ligands (Mertz, 1969; Norseth, 1979; Langard, 1980; Petrilli & De Flora, 1980) , the crucial site for the expression of Cr(VI) (carcino) genetic activity should be where Cr(VI) is converted to Cr(III). Only Cr(VI) reduction within the cell nucleus, and then only in the cells of target organs, could produce the interaction of Cr(III) with biological molecules relevant for the expression of carcinogenic effects. It is generally assumed that Cr exists within cells only in its reduced form, and Cr(III) is indeed detected, even after treatment with Cr(VI) compounds, by colorimetry (Levis et al., 1978a, b;  and in the present data), atomic absorption spectrophotometry (Feldman et al., 1967) and gas chromatography (Savory et al., 1970) . All these procedures, however, require wet decomposition of the biological samples with acidic mixtures which, in our experience, produce significant reduction of Cr(VI) to Cr(III) (see Methods). So we cannot exclude the possibility that limited amounts of Cr(VI), not reduced within the cytoplasm, reach the cell nucleus and react there with the DNA targets. The existence of Cr(VI) within root cells treated with potassium chromate has been demonstrated by Skeffington et al. (1976) by high-voltage paper electrophoresis.
It is noteworthy that Cr(VI) mutagenicity is decreased and even suppressed by the rat liver microsomal fraction, erythrocyte lysates, human gastric juice (Petrilli & De Flora, 1978a; Lofroth, 1978; De Flora & Boido, 1980; De Flora, 1978) and through reduction to Cr(III) by simple oxidoreduction, but it is not reduced by the microsomal fraction from rat muscle (Petrilli & De Flora, 1978a) and it is partially reduced by the microsomal preparations from rat lung, though far less efficiently than by the corresponding liver preparations (Petrilli & De Flora, 1980) . These observations correlate quite well with the preferential localization of Crinduced cancers in the human lung, with the lack of Cr(VI) oral carcinogenicity, with the development of tumours at implant sites (e.g. respiratory tract and muscles) in rodents treated with Cr(VI) compounds, and with the lack of carcinogenicity of Cr(III) compounds (IARC 1980) . Therefore only in the simplified in vitro test systems, where Cr(VI) is stable during long incubations (Bianchi et al., 1979; Umeda & Nishimura, 1979) and in the cells of in vivo target organs such as lungs and muscles, where Cr(VI) is not reduced by the microsomal fraction, could oxidized Cr(VI) reach the cell nucleus where it could be reduced to Cr(I1) on or near the critical target molecules. The very active conversion of Cr(VI) to Cr(1JJ) by erythrocytes (Langard, 1980) and by the microsomal fraction of liver cells (De Flora, 1978; Lofroth, 1978; Petrilli & De Flora, 1978a) represents an important mechanism of Cr(VI) inactivation in the organism.
Only chromates of medium (Ca chromate, Zn chromate hydroxide) or low (Sr and Pb chromates) water solubility, but not the very soluble Na and K chromates and dichromates, are carcinogenic in animals (IARC, 1980) but in vitro chromates and dichromates of high solubility have proved to be potent cytotoxic and mutagenic agents (see above references). The obvious explanation for the lack of carcinogenicity of high-solubility chromates is that, even though they may be potential mutagens, they disappear from the site of application very rapidly, and are eventually inactivated by erythrocytes (Langard, 1980) . In in vitro conditions we can keep compounds in the culture medium for a few days without dilution or inactivation. On the other hand lead chromate, which is known to be a fairly potent carcinogen (IARC, 1980) , was shown to induce point mutations in bacteria when solubilized in acids and alkalis (Nestmann et al., 1979; De Flora, 1981) , but it was inactive as a mutagen for bacteria and mammalian cells in culture when used as a fine suspension in water (Newbold et al., 1979; De Flora, 1981) . In view of the very low water solubility of this compound and the relatively short exposure in the in vitro experiments, their negative result is not surprising, neither it is in conflict with the positive carcinogenicity tests where the period of exposure is much longer and the material persists at the site of application so that significant exposure of cells to chromate ions from Pb chromate would be expected.
The state of oxidation is certainly the most important parameter to be taken into account when considering the biological activity of chromium compounds, but other properties, such as the solubility in water, the ability to permeate cell membranes and the intracellular stability of the oxidized Cr(VI) form (determining different retention and diffusion rates in vivo and in vitro) are relevant in producing differential effects in long-term carcinogenicity and short-term mutagenicity tests. Although there are still definite gaps in our understanding of the relationships between chromium mutagenicity and carcinogenicity, and the exact roles of soluble and insoluble Cr(VI) and Cr(III) compounds in carcinogenesis, the knowledge of the mutagenic, cytogenetic and cytotoxic powers of Cr(VI) and Cr(III) compounds is already sufficient for assessing their respective contributions as human hazards.
